Fosun Pharma

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Formerly	Shanghai Fortune Industrial; Shanghai Fosun Industrial;
Company type	listed
Traded as	; SSE MidCap Component;
SSE: 600196	(A share)
SEHK: 2196	(H share)
Industry	pharmaceutical; medical;
Founded	1994
Founder	Fosun High Technology; Guangxin Technology; and 3 others;
Headquarters	Shanghai, China
Key people
Chen Qiyu	(chairman)
Wu Yifang	(CEO)
Services	private hospitals
Net income	CN¥03.125 billion (2017)
Total assets	CN¥61.914 billion (2017)
Total equity	CN¥25.270 billion (2017)
Owner	Fosun Int'l (37.94%)
Subsidiaries
Sinopharm Industrial Investment	(joint venture, 49%)
Sisram Medical	(52.83%)
Gland Pharma	(12%)
Fosun Long March	(100%)
Fosun Industrial	(100%)
Chinese name
Simplified Chinese	上海复星医药（集团）股份有限公司
Traditional Chinese	上海復星醫藥（集團）股份有限公司
Hanyu Pinyin
Transcriptions
Standard Mandarin
Hanyu Pinyin	Shàng hǎi fù xīng yī yào (jí tuán) gǔ fèn yǒu xiàn gōng sī
Chinese short name
Simplified Chinese	复星医药
Traditional Chinese	復星醫藥
Hanyu Pinyin
Transcriptions
Standard Mandarin
Hanyu Pinyin	fù xīng yī yào
former Chinese short name
Simplified Chinese	复星实业
Traditional Chinese	復星實業
Hanyu Pinyin
Transcriptions
Standard Mandarin
Hanyu Pinyin	Fù xīng shí yè
Website	www.fosunpharma.com
	Footnotes / references; in consolidated financial statement

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (trade name: Fosun Pharma) is a Chinese pharmaceutical company. It is mostly owned by Fosun International.^[2]

As of 2018, the A shares of the company is a constituent of SSE 180 Index as well as its sub-index SSE MidCap Index.^[3] The company was ranked 1,840th in 2020 edition of the Forbes Global 2000, a list of top listed companies of the world.^[4]

^ 2017 Annual Report (PDF). Fosun Pharmaceutical. 17 April 2018. Retrieved 5 August 2018 – via Hong Kong Exchanges and Clearing website.
^ Li, Jane (3 April 2018). "Fosun Pharma chief cites Huawei as model for overseas expansion". South China Morning Post. Hong Kong. Retrieved 1 August 2018.
^ "SSE MidCap Constituents List" (Microsoft Excel). China Securities Index. Retrieved 5 August 2018.
^ "Shanghai Fosun Pharmaceutical". Forbes. Retrieved 20 December 2020.

[FosunPharma2017ARH-1] 2017 Annual Report (PDF). Fosun Pharmaceutical. 17 April 2018. Retrieved 5 August 2018 – via Hong Kong Exchanges and Clearing website.

[2] Li, Jane (3 April 2018). "Fosun Pharma chief cites Huawei as model for overseas expansion". South China Morning Post. Hong Kong. Retrieved 1 August 2018.

[3] "SSE MidCap Constituents List" (Microsoft Excel). China Securities Index. Retrieved 5 August 2018.

[4] "Shanghai Fosun Pharmaceutical". Forbes. Retrieved 20 December 2020.

[1]

[2]

[3]

[4]